DURHAM, NC – MARCH 21, 2013 – Zenalux Biomedical, Inc., a leader in biophotonic diagnostics, is now offering the Zenascope™ PC1, a biological tissue spectrometer that reliably, quickly and non-destructively measures biological tissue characteristics (biomarkers) that reflect underlying function and composition. The device is being used to detect the presence of cancer as well as other disease states and has also shown significant promise in monitoring therapy.
The Zenascope PC1 is an ultraviolet-visible spectrometer that achieves quantitative optical spectroscopy in turbid media. The system is a specialized, real-time, diagnostic device that shines white light on opaque target media and then measures and analyzes the reflected signal. Proprietary algorithms and standardized measurement hardware achieve rapid, quantitative analysis of targeted endpoints including hemoglobin concentration, hemoglobin saturation and scattering (a measure of cell density and necrosis). The system can also easily be tuned to include additional absorbers of interest. This unique capability is expected to enable improved diagnosis, better treatment and ultimately cost reduction in the health care system. Application areas currently include accelerating feedback in drug discovery; breast tumor margin assessment; response to therapy; breast biopsy; cervical cancer detection; and head and neck cancer detection.
"This technique gives us a fundamentally new approach to monitoring tumor physiology non-destructively and in real time," said Mark W. Dewhirst, DVM, PhD, the Gustavo S. Montana Professor of Radiation Oncology and Director of the Radiation Oncology Program of the Duke Comprehensive Cancer Center. “Using this approach we are in a much better position to evaluate treatment response and adjust our treatment strategies accordingly.”
The Zenascope™ PC1 is designated for pre-clinical use at this time. To learn more about the Zenascope and the technology, visit www.zenalux.com. Contact Zenalux at 2608 Erwin Road, Suite 148-164, Durham, NC 27705; call (919)-794-5757; email email@example.com.
About Zenalux Biomedical, Inc.
Zenalux Biomedical is a biomedical diagnostics start-up company that is developing novel biophotonic-based tools to aid in the diagnosis and treatment of cancer as well as other disease states. The company has established its leadership in biophotonics through its deep ties to Duke University. The company’s flagship product is the Zenascope, a patent-protected, photonic system that non-destructively measures dominant tissue chromophores (such as oxygenated hemoglobin, deoxygenated hemoglobin and beta-carotene) as well as changes in cellular morphology and density. Applications areas currently under study include: accelerating feedback in drug discovery, breast tumor margin assessment, breast biopsy, and cervical cancer and head and neck cancer detection. Zenalux Biomedical is based in Durham, N.C. Visit www.zenalux.com.